sarilumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	5237	1189541-98-7

Description:

Molecule	Description
Synonyms: sarilumab REGN88 SAR153191 kevzara	Sarilumab is a human recombinant monoclonal antibody of the IgG1 subclass. Sarilumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Sarilumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis. Based on encouraging results in China with a similar drug, tocilizumab, a phase 2/3 US study evaluating efficacy and safety of sarilumab in patients hospitalized with severe COVID-19 was performed. At the moment, there are insufficient data to recommend either for or against use of sarilumab for hospitalized patients with COVID-19. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

sarilumab
REGN88
SAR153191
kevzara

Sarilumab is a human recombinant monoclonal antibody of the IgG1 subclass. Sarilumab is produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Sarilumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes, and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis. Based on encouraging results in China with a similar drug, tocilizumab, a phase 2/3 US study evaluating efficacy and safety of sarilumab in patients hospitalized with severe COVID-19 was performed. At the moment, there are insufficient data to recommend either for or against use of sarilumab for hospitalized patients with COVID-19.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
14.30	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
June 23, 2017	EMA	sanofi-aventis groupe
May 22, 2017	FDA	SANOFI SYNTHELABO
Sept. 27, 2017	PMDA	SANOFI KK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rheumatoid factor positive	1497.72	53.89	1049	76156	83357	63328460
Anti-cyclic citrullinated peptide antibody positive	1453.43	53.89	1171	76034	115041	63296776
Wound	1205.92	53.89	1223	75982	162040	63249777
Pericarditis	1188.35	53.89	1101	76104	130478	63281339
Hand deformity	1187.75	53.89	1200	76005	158257	63253560
Hepatic enzyme increased	1152.73	53.89	1321	75884	201007	63210810
Synovitis	1139.04	53.89	1264	75941	185654	63226163
Glossodynia	1106.00	53.89	1219	75986	177657	63234160
Pemphigus	1063.86	53.89	1210	75995	182516	63229301
Discomfort	1021.30	53.89	1133	76072	166241	63245576
Joint swelling	1009.76	53.89	1584	75621	326082	63085735
Systemic lupus erythematosus	995.81	53.89	1246	75959	207672	63204145
Infusion related reaction	797.15	53.89	1217	75988	244304	63167513
Arthropathy	785.12	53.89	1180	76025	233612	63178205
Helicobacter infection	753.97	53.89	733	76472	92052	63319765
Duodenal ulcer perforation	723.69	53.89	697	76508	86512	63325305
Drug intolerance	705.95	53.89	1308	75897	307353	63104464
Swelling	699.89	53.89	1222	75983	274156	63137661
Abdominal discomfort	678.41	53.89	1315	75890	319570	63092247
Treatment failure	674.45	53.89	1007	76198	198036	63213781
Alopecia	671.12	53.89	1348	75857	336188	63075629
Rheumatic fever	601.28	53.89	464	76741	42647	63369170
Hypersensitivity	593.46	53.89	1179	76026	291506	63120311
Contraindicated product administered	572.22	53.89	981	76224	216667	63195150
Product use issue	552.40	53.89	973	76232	219547	63192270
Maternal exposure during pregnancy	544.80	53.89	966	76239	219096	63192721
Hip arthroplasty	543.74	53.89	456	76749	47190	63364627
Swollen joint count increased	526.79	53.89	399	76806	35655	63376162
Blood cholesterol increased	487.37	53.89	586	76619	93446	63318371
Knee arthroplasty	456.42	53.89	437	76768	53769	63358048
Type 2 diabetes mellitus	451.21	53.89	468	76737	63400	63348417
Blister	440.78	53.89	658	76547	129156	63282661
Condition aggravated	425.31	53.89	1260	75945	400957	63010860
General physical health deterioration	401.06	53.89	806	76399	200596	63211221
Therapeutic product effect decreased	365.47	53.89	757	76448	192430	63219387
Death	353.18	53.89	27	77178	374354	63037463
Pain	344.64	53.89	1789	75416	738839	62672978
Injury	314.93	53.89	416	76789	72831	63338986
Rash	309.16	53.89	1423	75782	559448	62852369
Musculoskeletal stiffness	305.02	53.89	685	76520	183933	63227884
Anaemia	298.25	53.89	14	77191	293416	63118401
Hypotension	290.72	53.89	9	77196	272595	63139222
Acute kidney injury	287.20	53.89	7	77198	263408	63148409
Fall	279.66	53.89	67	77138	392267	63019550
Toxicity to various agents	271.74	53.89	6	77199	247244	63164573
Drug interaction	258.15	53.89	4	77201	229127	63182690
Liver injury	245.23	53.89	334	76871	60186	63351631
Mobility decreased	238.54	53.89	483	76722	120676	63291141
Product use in unapproved indication	228.86	53.89	602	76603	178478	63233339
Intentional product use issue	220.57	53.89	483	76722	127409	63284408
Adverse event	214.21	53.89	332	76873	67227	63344590
Fibromyalgia	213.98	53.89	365	76840	80055	63331762
Constipation	212.55	53.89	16	77189	224927	63186890
Prescribed overdose	212.33	53.89	234	76971	33919	63377898
Adverse drug reaction	204.49	53.89	356	76849	79358	63332459
Folliculitis	201.56	53.89	330	76875	69987	63341830
Cough	198.86	53.89	55	77150	292688	63119129
Irritable bowel syndrome	195.91	53.89	356	76849	82056	63329761
Somnolence	186.53	53.89	7	77198	178678	63233139
Arthralgia	186.14	53.89	1256	75949	568454	62843363
Drug ineffective	185.70	53.89	2009	75196	1042756	62369061
Live birth	179.38	53.89	187	77018	25443	63386374
Muscle injury	175.67	53.89	298	76907	65047	63346770
Back pain	173.18	53.89	53	77152	264092	63147725
Psoriatic arthropathy	173.14	53.89	359	76846	91161	63320656
Diarrhoea	167.73	53.89	391	76814	714975	62696842
Dyspnoea	161.87	53.89	353	76852	660960	62750857
Blood pressure increased	157.49	53.89	10	77195	162052	63249765
Deep vein thrombosis postoperative	155.39	53.89	121	77084	11248	63400569
Urinary tract infection	151.72	53.89	66	77139	264618	63147199
Retinitis	150.82	53.89	94	77111	6102	63405715
Haemoglobin decreased	141.29	53.89	9	77196	145476	63266341
Sleep disorder due to general medical condition, insomnia type	140.16	53.89	238	76967	51979	63359838
Seizure	139.08	53.89	5	77200	132629	63279188
Tremor	135.23	53.89	6	77199	132233	63279584
Adjustment disorder with depressed mood	133.84	53.89	106	77099	10098	63401719
Lip dry	132.51	53.89	126	77079	15344	63396473
Thrombocytopenia	131.41	53.89	15	77190	151142	63260675
Renal failure	128.60	53.89	3	77202	117649	63294168
Facet joint syndrome	127.77	53.89	111	77094	12027	63399790
Dislocation of vertebra	126.99	53.89	96	77109	8539	63403278
Myalgia	126.24	53.89	15	77190	146514	63265303
Autoimmune disorder	121.40	53.89	126	77079	17051	63394766
Atrial fibrillation	120.23	53.89	5	77200	116631	63295186
Sepsis	119.55	53.89	21	77184	153102	63258715
Disease progression	118.00	53.89	8	77197	122750	63289067
Feeling abnormal	116.62	53.89	20	77185	148372	63263445
Loss of consciousness	115.61	53.89	7	77198	118114	63293703
Pulmonary embolism	111.00	53.89	8	77197	116676	63295141
Nausea	109.18	53.89	603	76602	853868	62557949
Joint range of motion decreased	107.85	53.89	163	77042	32265	63379552
Impaired healing	107.47	53.89	321	76884	102221	63309596
Peripheral venous disease	106.63	53.89	112	77093	15365	63396452
Respiratory failure	102.91	53.89	5	77200	101853	63309964
Hypokalaemia	102.05	53.89	6	77199	103798	63308019
Palpitations	101.05	53.89	10	77195	112760	63299057
Myocardial infarction	100.61	53.89	5	77200	99888	63311929
Weight decreased	100.58	53.89	113	77092	276685	63135132
Ill-defined disorder	100.37	53.89	271	76934	81484	63330333
Asthenia	100.13	53.89	197	77008	383407	63028410
Neutropenia	99.64	53.89	44	77161	174961	63236856
Hypercholesterolaemia	99.14	53.89	126	77079	21208	63390609
Hyperhidrosis	98.12	53.89	9	77196	107827	63303990
Lupus vulgaris	97.93	53.89	71	77134	5923	63405894
Cerebrovascular accident	95.70	53.89	10	77195	108014	63303803
Breast cancer stage III	95.50	53.89	88	77117	10298	63401519
Cardiac failure congestive	95.14	53.89	4	77201	92429	63319388
Hepatic cirrhosis	94.86	53.89	133	77072	24601	63387216
Oxygen saturation decreased	94.05	53.89	3	77202	88582	63323235
Dysphagia	94.05	53.89	3	77202	88582	63323235
Heart rate increased	94.02	53.89	5	77200	94233	63317584
Chest discomfort	92.89	53.89	12	77193	109957	63301860
Pleural effusion	92.82	53.89	5	77200	93205	63318612
Aspartate aminotransferase increased	92.60	53.89	4	77201	90273	63321544
Alanine aminotransferase increased	90.92	53.89	10	77195	103760	63308057
Chills	87.51	53.89	16	77189	113362	63298455
Grip strength decreased	87.20	53.89	121	77084	22166	63389651
Pneumonia	85.53	53.89	278	76927	456489	62955328
Vision blurred	85.46	53.89	7	77198	91917	63319900
Overdose	85.12	53.89	18	77187	115060	63296757
Abdominal pain	82.47	53.89	144	77061	293312	63118505
Cardiac failure	82.29	53.89	7	77198	89135	63322682
Platelet count decreased	82.21	53.89	20	77185	116102	63295715
Balance disorder	79.68	53.89	6	77199	84416	63327401
Erythema	78.94	53.89	59	77146	175692	63236125
Pyrexia	78.29	53.89	301	76904	470177	62941640
Bone erosion	78.18	53.89	102	77103	17615	63394202
Flushing	78.11	53.89	3	77202	75084	63336733
Joint dislocation	77.98	53.89	105	77100	18695	63393122
Drug tolerance decreased	77.74	53.89	101	77104	17372	63394445
Anti-cyclic citrullinated peptide antibody	77.66	53.89	65	77140	6693	63405124
Lupus-like syndrome	76.93	53.89	94	77111	15201	63396616
Deep vein thrombosis	76.22	53.89	7	77198	83793	63328024
Renal impairment	76.19	53.89	9	77196	88346	63323471
Epistaxis	75.33	53.89	3	77202	72722	63339095
Exostosis	74.45	53.89	100	77105	17762	63394055
Blood glucose increased	73.56	53.89	8	77197	83748	63328069
Tachycardia	73.33	53.89	26	77179	118130	63293687
Lower limb fracture	72.51	53.89	116	77089	24105	63387712
Loss of personal independence in daily activities	72.07	53.89	271	76934	97019	63314798
Pancytopenia	69.99	53.89	16	77189	96917	63314900
Joint stiffness	69.66	53.89	156	77049	41713	63370104
Oral discomfort	69.56	53.89	70	77135	9131	63402686
Stomatitis	69.30	53.89	343	76862	138382	63273435
Laryngitis	69.21	53.89	94	77111	16873	63394944
Osteoarthritis	68.50	53.89	263	76942	95080	63316737
Anxiety	68.41	53.89	99	77106	217442	63194375
Influenza	67.33	53.89	24	77181	108698	63303119
Bronchitis	67.12	53.89	34	77171	124901	63286916
C-reactive protein	66.80	53.89	52	77153	4830	63406987
Insomnia	66.67	53.89	99	77106	215153	63196664
Walking aid user	65.84	53.89	73	77132	10644	63401173
Wound infection	64.73	53.89	103	77102	21307	63390510
Prescribed underdose	63.93	53.89	123	77082	29566	63382251
Wrong technique in product usage process	63.15	53.89	3	77202	62337	63349480
Vomiting	62.23	53.89	412	76793	559205	62852612
Cardio-respiratory arrest	60.37	53.89	3	77202	59956	63351861
Haemorrhage	58.56	53.89	4	77201	61018	63350799
Dyspnoea exertional	57.73	53.89	4	77201	60298	63351519
Swelling face	55.89	53.89	6	77199	63469	63348348
C-reactive protein abnormal	55.74	53.89	152	77053	45944	63365873
Stress	55.13	53.89	8	77197	67159	63344658
Injection site reaction	54.60	53.89	176	77029	58348	63353469
Pulmonary oedema	54.45	53.89	3	77202	54870	63356947
Hallucination	54.38	53.89	3	77202	54814	63357003
Contusion	54.24	53.89	340	76865	149704	63262113

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Joint swelling	142.86	38.79	66	1666	59824	34895375
Pain	139.05	38.79	99	1633	204576	34750623
Drug ineffective	114.39	38.79	125	1607	456626	34498573
Arthralgia	107.71	38.79	79	1653	169962	34785237
Injection site pruritus	45.76	38.79	16	1716	6967	34948232
Product use in unapproved indication	45.21	38.79	41	1691	117458	34837741

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rheumatoid factor positive	1233.14	54.53	671	55373	59168	79629176
Anti-cyclic citrullinated peptide antibody positive	1221.75	54.53	748	55296	82395	79605949
Pemphigus	1170.25	54.53	778	55266	98804	79589540
Glossodynia	1153.60	54.53	782	55262	102555	79585789
Hand deformity	1147.23	54.53	781	55263	103138	79585206
Wound	1144.27	54.53	814	55230	115365	79572979
Systemic lupus erythematosus	1131.83	54.53	822	55222	120327	79568017
Pericarditis	1067.27	54.53	748	55296	103488	79584856
Synovitis	976.87	54.53	824	55220	149910	79538434
Discomfort	906.22	54.53	731	55313	124886	79563458
Hepatic enzyme increased	903.36	54.53	857	55187	181753	79506591
Joint swelling	890.54	54.53	1053	54991	287593	79400751
Arthropathy	809.51	54.53	796	55248	176315	79512029
Alopecia	763.05	54.53	874	55170	230481	79457863
Swelling	694.78	54.53	807	55237	215904	79472440
Helicobacter infection	691.43	54.53	491	55553	69213	79619131
Duodenal ulcer perforation	681.34	54.53	477	55567	65734	79622610
Abdominal discomfort	653.59	54.53	841	55203	249886	79438458
Maternal exposure during pregnancy	625.86	54.53	615	55429	135923	79552421
Contraindicated product administered	624.53	54.53	656	55388	156882	79531462
Rheumatic fever	595.67	54.53	323	55721	28202	79660142
Treatment failure	585.15	54.53	658	55386	169828	79518516
Drug intolerance	581.45	54.53	816	55228	263303	79425041
Infusion related reaction	579.11	54.53	759	55285	229478	79458866
Hypersensitivity	535.73	54.53	782	55262	261457	79426887
Hip arthroplasty	525.19	54.53	322	55722	35434	79652910
Blister	521.18	54.53	524	55520	118952	79569392
Swollen joint count increased	485.30	54.53	262	55782	22665	79665679
Product use issue	483.47	54.53	663	55381	209159	79479185
Blood cholesterol increased	445.90	54.53	410	55634	83310	79605034
Knee arthroplasty	438.68	54.53	309	55735	42939	79645405
Pain	407.71	54.53	1249	54795	702553	78985791
Type 2 diabetes mellitus	393.46	54.53	324	55720	56798	79631546
Therapeutic product effect decreased	375.99	54.53	517	55527	163346	79524998
Acute kidney injury	320.19	54.53	10	56034	519394	79168950
Injury	307.09	54.53	323	55721	77173	79611171
Death	305.19	54.53	25	56019	566489	79121855
Musculoskeletal stiffness	289.56	54.53	474	55570	174534	79513810
Irritable bowel syndrome	285.91	54.53	281	55763	61960	79626384
Fibromyalgia	283.57	54.53	284	55760	64056	79624288
Toxicity to various agents	280.25	54.53	3	56041	421537	79266807
Liver injury	277.73	54.53	265	55779	56349	79631995
Hypotension	273.02	54.53	8	56036	440309	79248035
Drug interaction	271.37	54.53	4	56040	415179	79273165
Folliculitis	269.34	54.53	258	55786	55122	79633222
Psoriatic arthropathy	260.19	54.53	297	55747	77702	79610642
Rash	259.66	54.53	943	55101	577415	79110929
Condition aggravated	258.69	54.53	856	55188	500268	79188076
Mobility decreased	249.77	54.53	365	55679	121810	79566534
Anaemia	244.14	54.53	18	56026	444997	79243347
General physical health deterioration	239.62	54.53	569	55475	274669	79413675
Muscle injury	239.49	54.53	228	55816	48333	79640011
Adverse event	220.91	54.53	241	55803	59973	79628371
Arthralgia	220.06	54.53	888	55156	570915	79117429
Sleep disorder due to general medical condition, insomnia type	213.82	54.53	204	55840	43352	79644992
Deep vein thrombosis postoperative	203.03	54.53	114	55930	10638	79677706
Prescribed overdose	198.54	54.53	184	55860	37699	79650645
Adverse drug reaction	183.86	54.53	230	55814	66162	79622182
Live birth	176.34	54.53	128	55916	18616	79669728
Lip dry	174.70	54.53	118	55926	15300	79673044
Drug ineffective	174.65	54.53	1325	54719	1079588	78608756
Fall	172.01	54.53	64	55980	487565	79200779
Facet joint syndrome	171.52	54.53	104	55940	11198	79677146
Autoimmune disorder	166.74	54.53	118	55926	16494	79671850
Impaired healing	163.51	54.53	251	55793	87404	79600940
Constipation	162.39	54.53	9	56035	283041	79405303
Retinitis	161.36	54.53	79	55965	5564	79682780
Product use in unapproved indication	157.78	54.53	459	55585	249900	79438444
Intentional product use issue	153.86	54.53	334	55710	151778	79536566
Exposure during pregnancy	152.52	54.53	263	55781	100869	79587475
Adjustment disorder with depressed mood	149.30	54.53	88	55956	8998	79679346
Ill-defined disorder	143.58	54.53	203	55841	65672	79622672
Peripheral venous disease	139.20	54.53	104	55940	15805	79672539
Cough	136.40	54.53	44	56000	366745	79321599
Somnolence	135.83	54.53	8	56036	238973	79449371
Joint range of motion decreased	134.02	54.53	140	55904	33142	79655202
Dislocation of vertebra	131.26	54.53	77	55967	7803	79680541
Thrombocytopenia	128.97	54.53	17	56027	265242	79423102
Osteoarthritis	126.36	54.53	223	55821	87086	79601258
Stomatitis	124.87	54.53	301	55743	146456	79541888
Blood pressure increased	123.47	54.53	6	56038	211354	79476990
Breast cancer stage III	122.93	54.53	80	55964	9746	79678598
Dyspnoea	120.76	54.53	265	55779	856760	78831584
Haemoglobin decreased	118.82	54.53	10	56034	222109	79466235
Seizure	118.49	54.53	3	56041	188831	79499513
Lower limb fracture	118.23	54.53	111	55933	23104	79665240
Sepsis	116.02	54.53	24	56020	269404	79418940
Grip strength decreased	112.21	54.53	105	55939	21764	79666580
Atrial fibrillation	111.31	54.53	7	56037	197879	79490465
Renal failure	107.62	54.53	9	56035	200959	79487385
Hypoaesthesia	102.65	54.53	318	55726	179034	79509310
Respiratory failure	99.98	54.53	7	56037	180904	79507440
Disease progression	99.42	54.53	8	56036	184354	79503990
Joint dislocation	98.00	54.53	87	55957	16852	79671492
Loss of consciousness	97.34	54.53	5	56039	167938	79520406
Myocardial infarction	96.54	54.53	9	56035	184120	79504224
Exostosis	96.37	54.53	86	55958	16772	79671572
Back pain	95.83	54.53	47	55997	304133	79384211
Tremor	95.70	54.53	6	56038	170077	79518267
Bone erosion	94.09	54.53	87	55957	17760	79670584
Lupus-like syndrome	94.07	54.53	78	55966	13779	79674565
C-reactive protein abnormal	89.44	54.53	138	55906	48229	79640115
C-reactive protein	89.16	54.53	51	55993	4928	79683416
Cardiac arrest	88.68	54.53	9	56035	172087	79516257
Sciatica	88.61	54.53	113	55931	33109	79655235
Joint stiffness	87.73	54.53	125	55919	40705	79647639
Hypercholesterolaemia	87.38	54.53	94	55950	23001	79665343
Pneumonia	87.31	54.53	211	55833	660035	79028309
Gastrointestinal haemorrhage	86.88	54.53	4	56040	147715	79540629
Laryngitis	86.14	54.53	79	55965	15960	79672384
Alanine aminotransferase increased	85.08	54.53	8	56036	162562	79525782
Platelet count decreased	84.49	54.53	17	56027	194647	79493697
Anti-cyclic citrullinated peptide antibody	84.07	54.53	52	55992	5800	79682544
Pulmonary embolism	83.40	54.53	11	56033	171643	79516701
Bursitis	83.37	54.53	114	55930	35730	79652614
Diarrhoea	83.36	54.53	328	55716	880161	78808183
Hyperhidrosis	83.30	54.53	6	56038	151486	79536858
Cardiac failure congestive	83.28	54.53	4	56040	142398	79545946
Lower respiratory tract infection	83.28	54.53	239	55805	128981	79559363
Urinary tract infection	81.17	54.53	46	55998	274466	79413878
Neutropenia	81.16	54.53	51	55993	287659	79400685
Aspartate aminotransferase increased	80.74	54.53	4	56040	138637	79549707
Cerebrovascular accident	80.32	54.53	8	56036	155284	79533060
Cardiac failure	80.03	54.53	8	56036	154834	79533510
Contusion	79.80	54.53	258	55786	148518	79539826
Infection	78.32	54.53	357	55687	241355	79446989
Gait inability	78.23	54.53	145	55899	58772	79629572
Overdose	78.06	54.53	17	56027	184189	79504155
Renal impairment	76.92	54.53	10	56034	157773	79530571
Night sweats	76.56	54.53	134	55910	51961	79636383
Hypokalaemia	75.61	54.53	7	56037	144033	79544311
Myalgia	74.97	54.53	19	56025	185622	79502722
Walking aid user	74.94	54.53	60	55984	10088	79678256
Wound infection	74.31	54.53	88	55956	23903	79664441
Oxygen saturation decreased	74.28	54.53	4	56040	129043	79559301
Lupus vulgaris	72.89	54.53	39	56005	3307	79685037
Bradycardia	72.75	54.53	6	56038	135551	79552793
Foot deformity	72.42	54.53	87	55957	23987	79664357
Palpitations	69.65	54.53	5	56039	126605	79561739
Dysphagia	69.63	54.53	4	56040	122132	79566212
Heart rate increased	68.69	54.53	4	56040	120720	79567624
Injection site pruritus	67.71	54.53	113	55931	42170	79646174
Road traffic accident	66.36	54.53	114	55930	43550	79644794
Pleural effusion	64.47	54.53	12	56032	145250	79543094
Chills	63.55	54.53	17	56027	160217	79528127
Loss of personal independence in daily activities	63.45	54.53	187	55857	102393	79585951
Pancytopenia	63.12	54.53	19	56025	165726	79522618
Gastrointestinal disorder	62.89	54.53	209	55835	121996	79566348
Hepatic cirrhosis	62.31	54.53	98	55946	34808	79653536
Chest discomfort	62.14	54.53	11	56033	138033	79550311
Wheezing	61.35	54.53	201	55843	116463	79571881
Weight decreased	61.15	54.53	97	55947	355101	79333243
Deep vein thrombosis	60.56	54.53	7	56037	120912	79567432
Nausea	60.32	54.53	410	55634	956786	78731558
Tachycardia	59.80	54.53	25	56019	177743	79510601
Epistaxis	59.66	54.53	5	56039	111510	79576834
Feeling abnormal	59.27	54.53	19	56025	159180	79529164
Vision blurred	58.78	54.53	4	56040	105894	79582450
Abdominal pain	58.39	54.53	116	55928	389453	79298891
Pyrexia	57.83	54.53	263	55781	678446	79009898
Obesity	57.76	54.53	95	55949	35030	79653314
Cardio-respiratory arrest	57.68	54.53	5	56039	108505	79579839
Injection site reaction	57.27	54.53	122	55922	54663	79633681
Balance disorder	57.09	54.53	3	56041	98854	79589490
X-ray abnormal	55.36	54.53	40	56004	5773	79682571

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC14	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA MoA	N0000190478	Interleukin 6 Receptor Antagonists
FDA EPC	N0000190480	Interleukin-6 Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Bacterial infectious disease	contraindication	87628006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-6 receptor	Membrane receptor	P08887 P40189	IL6RA_HUMAN IL6RB_HUMAN	ANTIBODY BINDING	Kd	11.10		IUPHAR	DRUG LABEL

External reference:

ID	Source
NU90V55F8I	UNII
4036706	VANDF
C3885145	UMLSCUI
CHEMBL2108730	ChEMBL_ID
DB11767	DRUGBANK_ID
D10161	KEGG_DRUG
9476	INN_ID
7999	IUPHAR_LIGAND_ID
257686	MMSL
32766	MMSL
d08592	MMSL
017137	NDDF
735231009	SNOMEDCT_US
763522001	SNOMEDCT_US
1923319	RXNORM
C000592401	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5908	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5908	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5910	INJECTION, SOLUTION	200 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5910	INJECTION, SOLUTION	200 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5920	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5920	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5922	INJECTION, SOLUTION	200 mg	SUBCUTANEOUS	BLA	31 sections
KEVZARA	HUMAN PRESCRIPTION DRUG LABEL	1	0024-5922	INJECTION, SOLUTION	200 mg	SUBCUTANEOUS	BLA	31 sections